K.J. Lillywhite

741 total citations
12 papers, 667 citations indexed

About

K.J. Lillywhite is a scholar working on Pharmacology, Pharmacology and Oncology. According to data from OpenAlex, K.J. Lillywhite has authored 12 papers receiving a total of 667 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Pharmacology and 4 papers in Oncology. Recurrent topics in K.J. Lillywhite's work include Pharmacogenetics and Drug Metabolism (6 papers), Glycosylation and Glycoproteins Research (2 papers) and Analytical Methods in Pharmaceuticals (2 papers). K.J. Lillywhite is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Glycosylation and Glycoproteins Research (2 papers) and Analytical Methods in Pharmaceuticals (2 papers). K.J. Lillywhite collaborates with scholars based in Australia and Thailand. K.J. Lillywhite's co-authors include John O. Miners, Peter I. Mackenzie, Chunjing Jin, Donald Birkett, D. J. Birkett, Luísa M.P. Valente, Michael E. Jones, Sompon Wanwimolruk, Lindon Wing and Brian Burchell and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Journal of Pharmacology and Experimental Therapeutics and Biochemical Pharmacology.

In The Last Decade

K.J. Lillywhite

12 papers receiving 637 citations

Peers

K.J. Lillywhite

PHARM

ONCOL

PPCH

PHARM

P Bechtel France

E Jacqz United States

Susumu Imaoka Japan

Yoshihiko Funae Japan

T.P. Sloan United Kingdom

Karl Ludwig Rost Germany

Leif Bertilsson Sweden

Toshio Yasumori Japan

R J Chenery United States

D. Kadar Canada

P Bechtel France

K.J. Lillywhite

495 ×1.1

PHARM

201 ×0.9

ONCOL

177 ×0.9

110 ×0.7

PPCH

198 ×1.6

PHARM

Citations per year, relative to K.J. Lillywhite K.J. Lillywhite (= 1×) peers P Bechtel

Countries citing papers authored by K.J. Lillywhite

Since Specialization

Citations

This map shows the geographic impact of K.J. Lillywhite's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.J. Lillywhite with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.J. Lillywhite more than expected).

Fields of papers citing papers by K.J. Lillywhite

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.J. Lillywhite. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.J. Lillywhite. The network helps show where K.J. Lillywhite may publish in the future.

Co-authorship network of co-authors of K.J. Lillywhite

This figure shows the co-authorship network connecting the top 25 collaborators of K.J. Lillywhite. A scholar is included among the top collaborators of K.J. Lillywhite based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.J. Lillywhite. K.J. Lillywhite is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Miners, John O., Luísa M.P. Valente, K.J. Lillywhite, et al.. (1997). Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug.. PubMed. 57(2). 284–9. 58 indexed citations

Birkett, D. J., John O. Miners, Luísa M.P. Valente, K.J. Lillywhite, & Richard O. Day. (1997). 1‐Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect. British Journal of Clinical Pharmacology. 43(2). 197–200. 7 indexed citations

Jin, Chunjing, John O. Miners, K.J. Lillywhite, & Peter I. Mackenzie. (1993). Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs.. Journal of Pharmacology and Experimental Therapeutics. 264(1). 475–479. 211 indexed citations

Miners, John O., et al.. (1993). cDNA Cloning and Expression of Two New Members of the Human Liver UDP-Glucuronosyltransferase 2B Subfamily. Biochemical and Biophysical Research Communications. 194(1). 496–503. 101 indexed citations

Miners, John O., et al.. (1990). Characterization of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes. Biochemical Pharmacology. 40(3). 595–600. 34 indexed citations

Miners, John O., K.J. Lillywhite, & Donald Birkett. (1988). In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation. Biochemical Pharmacology. 37(14). 2839–2845. 51 indexed citations

Miners, John O., et al.. (1988). Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. Biochemical Pharmacology. 37(4). 665–671. 52 indexed citations

Robson, Richard A., et al.. (1985). The effect of ranitidine on the disposition of lignocaine.. British Journal of Clinical Pharmacology. 20(2). 170–173. 21 indexed citations

Miners, John O., et al.. (1985). Verapamil disposition‐effects of sulphinpyrazone and cimetidine.. British Journal of Clinical Pharmacology. 19(3). 385–391. 26 indexed citations

10.

Miners, John O., et al.. (1985). Selectivity and dose‐dependency of the inhibitory effect of propranolol on theophylline metabolism in man.. British Journal of Clinical Pharmacology. 20(3). 219–223. 29 indexed citations

11.

Miners, John O., et al.. (1984). Failure of ‘therapeutic’ doses of beta‐adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine.. British Journal of Clinical Pharmacology. 18(6). 853–860. 25 indexed citations

12.

Wing, Lindon, et al.. (1984). Lidocaine disposition—Sex differences and effects of cimetidine. Clinical Pharmacology & Therapeutics. 35(5). 695–701. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact